JP2021521275A5 - - Google Patents

Info

Publication number
JP2021521275A5
JP2021521275A5 JP2021504593A JP2021504593A JP2021521275A5 JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5 JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021504593 A JP2021504593 A JP 2021504593A JP 2021521275 A5 JP2021521275 A5 JP 2021521275A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
binding protein
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/053040 external-priority patent/WO2019198051A2/en
Publication of JP2021521275A publication Critical patent/JP2021521275A/ja
Publication of JP2021521275A5 publication Critical patent/JP2021521275A5/ja
Priority to JP2025006634A priority Critical patent/JP2025081307A/ja
Pending legal-status Critical Current

Links

JP2021504593A 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物 Pending JP2021521275A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006634A JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18167384.9 2018-04-13
EP18167385.6 2018-04-13
EP18167384 2018-04-13
EP18167385 2018-04-13
EP18190662 2018-08-24
EP18190661.1 2018-08-24
EP18190661 2018-08-24
EP18190662.9 2018-08-24
PCT/IB2019/053040 WO2019198051A2 (en) 2018-04-13 2019-04-12 Nk cell engaging antibody fusion constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006634A Division JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Publications (2)

Publication Number Publication Date
JP2021521275A JP2021521275A (ja) 2021-08-26
JP2021521275A5 true JP2021521275A5 (enExample) 2022-04-20

Family

ID=66625219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504593A Pending JP2021521275A (ja) 2018-04-13 2019-04-12 Ｎｋ細胞結合抗体融合構築物
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006634A Pending JP2025081307A (ja) 2018-04-13 2025-01-17 Ｎｋ細胞結合抗体融合構築物

Country Status (21)

Country Link
US (3) US11001633B2 (enExample)
EP (1) EP3774914A2 (enExample)
JP (2) JP2021521275A (enExample)
KR (1) KR20200143436A (enExample)
CN (3) CN113817066A (enExample)
AU (2) AU2019252970A1 (enExample)
BR (1) BR112020020828A2 (enExample)
CA (1) CA3095373A1 (enExample)
CL (2) CL2020002625A1 (enExample)
CO (1) CO2020014167A2 (enExample)
CR (1) CR20200549A (enExample)
IL (1) IL277925A (enExample)
MA (1) MA52227A (enExample)
MX (1) MX2020010728A (enExample)
PE (1) PE20201346A1 (enExample)
PH (1) PH12020551664B1 (enExample)
RU (1) RU2022105827A (enExample)
SG (1) SG11202010064QA (enExample)
TW (1) TW202012441A (enExample)
WO (1) WO2019198051A2 (enExample)
ZA (1) ZA202006325B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
US12698331B2 (en) 2019-12-10 2026-08-04 Institut Pasteur Antibody blocking human FcγRIIIA and FcγRIIIB
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
TW202233248A (zh) * 2020-11-08 2022-09-01 美商西健公司 組合療法
MX2023006573A (es) * 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
US20240101677A1 (en) * 2021-01-27 2024-03-28 Innovent Biologics (Suzhou) Co., Ltd. Single-domain antibody against cd16a and use thereof
JP2024516230A (ja) 2021-04-30 2024-04-12 ジェネンテック， インコーポレイテッド がんのための治療及び診断方法並びに組成物
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
US20250206823A1 (en) * 2021-07-30 2025-06-26 Qure Biotechnology (Shanghai) Co., Ltd. Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
CA3233085A1 (en) * 2021-09-24 2023-03-30 Synergy Imt, Inc. Composition of recombinant antigen binding molecules and method of making and using thereof
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
CN116284385A (zh) * 2021-12-07 2023-06-23 信达细胞制药(苏州)有限公司 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
CN114349869B (zh) * 2021-12-20 2023-09-26 上海恩凯细胞技术有限公司 一种双特异性的nk细胞激动剂及制备方法和应用
JP2025528087A (ja) * 2022-08-05 2025-08-26 チマゲン・バイオサイエンシズ，リミテッド 二量体化可能な腫瘍抗原及び免疫刺激抗原を標的とする多重特異性抗体
AU2023343472A1 (en) * 2022-09-14 2025-03-20 Otsuka Pharmaceutical Co., Ltd. Pd-1 agonist antibodies
JP2026504499A (ja) * 2023-02-06 2026-02-05 レプ バイオファーマ カンパニー， リミテッド 抗ｃｄ１６ａ抗体およびその使用
KR20240136856A (ko) * 2023-03-06 2024-09-19 주식회사 드노보 바이오테라퓨틱스 신규한 항-cd16 항체 및 이의 용도
WO2025257588A1 (en) * 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products
WO2026101948A1 (en) * 2024-11-05 2026-05-15 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP4751777A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor
EP4751731A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane
EP4751734A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Bispecific antibody construct dosage regimen for treating nsclc
CN121362261A (zh) * 2025-10-30 2026-01-20 北京再青生物科技有限公司 一种靶向T细胞及Her2的双特异性抗体并串联IL-15及其受体的融合蛋白及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
LT2361936T (lt) * 2010-02-25 2016-09-12 Affimed Gmbh Antigeną rišanti molekulė ir jos panaudojimas
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013138643A1 (en) 2012-03-16 2013-09-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Soluble engineered monomeric fc
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP2970485A1 (en) * 2013-03-15 2016-01-20 Merck Patent GmbH Tetravalent bispecific antibodies
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
CA2983706C (en) * 2015-05-04 2024-01-02 Affimed Gmbh Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
WO2018158349A1 (en) * 2017-02-28 2018-09-07 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
KR102607909B1 (ko) 항-cd28 조성물
RU2022105827A (ru) Слитые конструкции антител для вовлечения nk-клеток
JP7450684B2 (ja) 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法
US11932675B2 (en) PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties
JP2025061672A (ja) Ｅｎｐｐ３およびｃｄ３に結合するヘテロ二量体抗体
JP2018525382A5 (enExample)
IL268836B1 (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
JP7080219B2 (ja) 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
JP2023159379A (ja) Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
JP2023550419A5 (enExample)
US20250043001A1 (en) Anti-cd28 compositions
US20250122299A1 (en) ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
JP2025504795A5 (enExample)
US20250084186A1 (en) Anti-cd28 x anti-enpp3 antibodies
CN121311507A (zh) 抗cd28 x抗trop2抗体
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
CN121311245A (zh) 用于治疗多发性骨髓瘤的方法
CA3212336A1 (en) Methods for treating multiple myeloma
WO2025090973A2 (en) Anti-trop2 x anti-pdl1 x anti-cd28 antibodies
CN116547306A (zh) 抗cd28和/或抗b7h3组合物
RU2023101035A (ru) Антитела к pd-1 и слитые белки
RU2020134591A (ru) Слитые конструкции антител для вовлечения nk-клеток
HK40047548A (en) Heterodimeric antibodies that bind fibroblast activation protein